Premium
Pregnancy Outcome and Mitral Valve Prolapse
Author(s) -
Chia Y. T.,
Yeoh S. C.,
Lim M.C.L.,
Viegas O. A.,
Ratnam S. S.
Publication year - 1994
Publication title -
asia‐oceania journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 0389-2328
DOI - 10.1111/j.1447-0756.1994.tb00485.x
Subject(s) - medicine , mitral valve prolapse , pregnancy , mitral regurgitation , gestation , mitral valve , obstetrics , vaginal delivery , surgery , genetics , biology
Mitral valve prolapse (MVP) comprises a large proportion of obstetric cardiac problems and has a general prevalence of 4%. We examined the obstetric outcome of patients with MVP delivered between 1988—1991 at the National University Hospital, Singapore. During this interval, deliveries totalled 16,755 of which 85 (0.51%) had maternal cardiac disease. Of these, 28 (32.9%) had echocardiographic evidence of non‐myxomatous MVP. Ten patients (37.5%) had demonstrable mitral regurgitation and 4 (14.3%) had benign ventricular ectopics. All patients remained well throughout pregnancy. Gestation at delivery and use of analgesia did not differ significantly from non‐cardiac patients. However, the labour induction rate was twice the department average at 17.9%. Twenty‐four (85.7%) patients achieved vaginal delivery and 4 (14.3%) patients were delivered abdominally. All babies were liveborn. Eight patients (28.6%) did not receive antibiotic prophylaxis during labour and postpartum period and remained afebrile. The role of antibiotics in this category of patients is discussed. Patients with MVP without myxomatous valve changes may expect excellent pregnancy outcome.